In one third of hepatocellular carcinomas (HCCs), cancer cells have mutations that activate beta catenin pathway. These cells have alterations in glutamine, bile, and lipid metabolism. We investigated whether positron emission tomography (PET) imaging allows identification of altered metabolic pathways that might be targeted therapeutically.